4.7 Article

Mislocated FUS is sufficient for gain-of-toxic-function amyotrophic lateral sclerosis phenotypes in mice

Journal

BRAIN
Volume 139, Issue -, Pages 2380-2394

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/brain/aww161

Keywords

TDP-43; amyotrophic lateral sclerosis; frontotemporal lobar degeneration; protein aggregation; RNA processing

Funding

  1. Eisai Co. Ltd.
  2. Foundation of Japan Amyotrophic Lateral Sclerosis Association
  3. Novartis Pharma
  4. Brain Science Foundation
  5. Life Science Foundation of Japan
  6. Ministry of Education, Culture, Sports, Science and Technology of Japan [15K09323]
  7. Nakabayashi Trust for ALS Research
  8. Kaken Grants-in-AID for Scientific Research [24890228]
  9. Grants-in-Aid for Scientific Research [16J05812, 24890228, 15K09323] Funding Source: KAKEN

Ask authors/readers for more resources

Mutations in RNA-binding proteins, including fused in sarcoma (FUS) and TAR DNA-binding protein 43 (TDP-43, encoded by TARDBP), are associated with sporadic and familial amyotrophic lateral sclerosis. A major question is whether neuronal loss is caused by toxic gain-of-function cytoplasmic aggregates or loss of nuclear RNA-binding protein function. We generated a transgenic mouse overexpressing exogenous FUS without a nuclear localization signal (Delta NLS-FUS), which developed progressive spastic motor deficits and neuronal loss in the motor cortex. The Delta NLS-FUS protein was restricted to the cytoplasm and formed ubiquitin/p62-positive aggregates. Endogenous FUS expression, nuclear localization, and splicing activity were not altered, indicating that mislocated FUS is sufficient for proteinopathy. Crossing Delta NLS-FUS with wild-type human TDP-43 transgenic mice exacerbated pathological and behavioural phenotypes, suggesting that both proteins are involved in a common cascade. RNA-sequence analysis revealed specific transcriptome alterations, including genes regulating dynein-associated molecules and endoplasmic reticulum stress. Delta NLS-FUS mice are promising tools for understanding amyotrophic lateral sclerosis pathogenesis and testing new therapeutic approaches.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available